Important regulatory milestone marks development into clinical-stage building of next-generation RNAi remedy that includes an cutting edge, built-in systemic remedy supply manner concentrated on extremely prevalent KRAS-driven cancers with vital unmet scientific want
Corporate reported sturdy sure preclinical learn about effects demonstrating vital anti-tumor job in more than one fashions and introduced a success of completion of toxicology research, and positive regulatory engagement supporting the Segment 2/3 trial design
Silexion expects to begin human medical trials in the second one quarter of 2026
Grand Cayman, Cayman Islands, March 24, 2026 (GLOBE NEWSWIRE) — / CORRECTING / Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology corporate, nowadays introduced that it has won formal approval from the Israeli Ministry of Well being to begin its Segment 2/3 medical trial comparing SIL204 for the remedy of in the neighborhood complicated pancreatic most cancers, following sure preclinical effects that demonstrated vital anti-tumor job in mulitple fashions along a success of completion of toxicology research.
This approval represents a significant regulatory milestone and a important development for the Corporate, enabling the transition of SIL204 into human medical analysis and positioning Silexion as a clinical-stage biotechnology corporate desirous about KRAS-driven cancers.
SIL204 is designed to silence KRAS mutations, which might be found in over 90% of pancreatic cancers and are widely known as one of the difficult goals in oncology. Not like mutation-specific approaches, SIL204 is engineered to focus on a extensive vary of KRAS mutations, supporting its possible applicability throughout more than one high-value most cancers indications.
The approval follows a sequence of primary sure trends completed via the Corporate, together with sturdy sure anti-tumor job demonstrated in more than one preclinical fashions, a success of completion of toxicology research, and positive regulatory engagement supporting the Segment 2/3 trial design. In combination, those achievements have enabled SIL204 to advance towards clinical-stage building. The Corporate additionally plans to publish a Segment 2/3 medical trial software in Germany via the tip of this present quarter, with further regulatory filings around the Eu Union deliberate in early 2027.
“The receipt of this approval marks a defining and highly significant milestone for Silexion,” stated Ilan Hadar, Chairman and Leader Government Officer of Silexion Therapeutics. “We are now advancing SIL204 into a pivotal clinical trial with the goal of addressing KRAS-driven cancers at their source. This progress reflects the strength of our data, the safety demonstrated during the Loder (predecessor to SIL204) clinical trial, the urgency of the unmet need in pancreatic cancer, and our continued execution toward developing a potentially transformative therapy.”
The Corporate expects to begin the Segment 2/3 trial in the second one quarter of 2026, topic to website activation and same old medical readiness procedures, and plans to advance SIL204 as a possible remedy throughout further KRAS-driven indications, together with colorectal and lung cancers.*
About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology corporate devoted to the improvement of cutting edge therapies for unsatisfactorily handled cast tumor cancers that experience the mutated KRAS oncogene, most often thought to be to be the most typical oncogenic gene driving force in human cancers. The Corporate performed a Segment 2a medical trial in its first-generation product, which confirmed a good pattern compared to the regulate of chemotherapy on my own. Silexion is dedicated to pushing the limits of healing developments within the box of oncology and additional creating its lead product candidate for in the neighborhood complicated pancreatic most cancers. For more info, please discuss with: https://silexion.com
Realize Relating to Ahead-Having a look Statements:This press unencumber comprises forward-looking statements throughout the which means of the federal securities rules. All statements rather than statements of ancient truth contained on this verbal exchange, together with, for instance, statements in regards to the initiation, timing, design, and habits of the deliberate Segment 2/3 medical trial of SIL204, together with anticipated trial graduation in the second one quarter of 2026 and affected person enrollment; the timing, content material, and end result of regulatory submissions and interactions with regulatory government in Israel, Germany, the Eu Union, and different jurisdictions; the development of SIL204 into clinical-stage building; the possible healing advantages and medical software of SIL204 throughout KRAS-driven cancers; the Corporate’s plans to make bigger building into further indications, together with colorectal and lung cancers; the Corporate’s building technique and expected milestones; its skill to boost further capital and fund operations; and its skill to deal with its Nasdaq record, are forward-looking statements. Those forward-looking statements are most often recognized via terminology comparable to “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of those phrases or permutations of them or equivalent terminology. Ahead-looking statements contain plenty of dangers, uncertainties, and assumptions, and precise effects or occasions might vary materially from the ones projected or implied in the ones statements. Essential elements that might reason such variations come with, however don’t seem to be restricted to: (i) Silexion’s skill to effectively whole preclinical research and begin medical trials; (ii) Silexion’s technique, long term operations, monetary place, projected prices, potentialities, and plans; (iii) the have an effect on of the regulatory surroundings and compliance complexities; (iv) expectancies relating to long term partnerships or different relationships with 3rd events; (v) Silexion’s long term capital necessities and assets and makes use of of money, together with its skill to acquire further capital; (vi) Silexion’s skill to deal with its Nasdaq record; and (vii) different dangers and uncertainties set forth within the paperwork filed via the Corporate with the SEC, together with the Corporate’s Annual File on Shape 10-Ok for the 12 months ended December 31, 2025, filed with the SEC on March 17, 2026. Silexion cautions you towards hanging undue reliance on forward-looking statements, which replicate present ideals and are in line with data recently to be had as of the date a forward-looking observation is made. Ahead-looking statements set forth herein discuss most effective as of the date they’re made. Silexion undertakes no legal responsibility to revise forward-looking statements to replicate long term occasions, adjustments in cases, or adjustments in ideals, excluding as in a different way required via regulation.
*In a prior model of this unencumber the general sentence within the frame of the discharge had unintentionally been left out. This model now contains that sentence which used to be bolded. No subject matter data used to be left out from the unique unencumber.
